Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

CU Anschutz clinical trial finds GLP-1s help curb alcohol use disorder

10 August 2026 · By · Wire by Fusion42

Published

10 August 2026

Topic

opportunities

◆ Sectors

Health: Drug Discovery

◆ Geography

United States

◆ Source

Read at health.yahoo.com →

◆ Verified

Fusion42 · 26 August 2026 · Fusion42 review

A clinical trial led by CU Anschutz found that semaglutide, a drug used for diabetes and weight loss, significantly reduced heavy drinking and alcohol cravings in people with alcohol use disorder.

This Wire brief sits within Fusion42's coverage of Health: Drug Discovery, and 2 sources have reported it.

◆ ◆ The Wire takeaway

The discovery that semaglutide controls alcohol cravings creates a new treatment path for drug developers in addiction. You can pivot to leverage this breakthrough and start exploring GLP-1 based therapies for addictive behaviours now.

◆ Coverage

2 sources · 10 Aug 2026

◆ Related on Wire

◆ Topics

Health: Drug Discoveryalcohol-use-disorderclinical-trialdrug-discoverysemaglutideaddiction-treatment